The initiation and progression of neuroinflammation cause structural and functional damage to both neurons and glial cells in the central nervous system. Early intervention to inhibit neuroinflammation could therefore prevent irreversible damage to nervous tissue before it accumulates. Current pharmacological options, however, carry burdens. The review notes that the glucocorticosteroids and nonsteroidal anti-inflammatory drugs now applied in neurological disorders pose a risk of injury to the cardiovascular, gastrointestinal, respiratory, hepatic, and renal systems, limiting their long-term suitability for chronic conditions.

As substitutes, the authors point to bioactive phytochemicals derived from dietary herbal medicines that have demonstrated anti-inflammatory activity. These compounds could serve as effective alternatives to conventional anti-inflammatory drugs. Yet the evidence base remains uneven: very few of these phytochemicals have undergone clinical trials demonstrating efficacy and safety, and several limitations—including lower bioavailability, solubility, and stability—hinder their clinical use.

The review’s purpose is to identify preclinical data on multiple dietary bioactive phytochemicals with robust anti-neuroinflammatory effects that could be considered for clinical trials. Drawing on what the authors describe as sufficient, efficacious, and predominantly preclinical data, it highlights the need for future modifications to enhance bioavailability while maintaining or improving therapeutic efficacy and reducing systemic side effects. Notably, the authors argue that this formulation-focused agenda should take priority over evaluating the compounds’ potency in newer disease models or exploring additional mechanisms of action—a deliberate redirection of research effort toward translational barriers rather than further mechanistic discovery.

The review also sets out a prioritization strategy. It calls for identifying top-tier phytochemicals, or combinations of them, that exhibit high bioavailability, optimal dosing, and proven long-term safety, while minimizing drug interactions and systemic toxicity. To make such comparisons meaningful across laboratories, the authors propose screening candidates through a standardized set of preclinical studies before advancing the most promising agents toward human testing. In their framing, managing chronic neuroinflammation with phytochemicals depends less on finding new compounds and more on systematically optimizing the delivery, dosing, and safety profiles of candidates already supported by robust preclinical evidence—an approach the authors present as the essential next step for moving these dietary molecules from bench toward clinical evaluation.

Subject of Research: Dietary phytochemicals as anti-neuroinflammatory therapeutic candidates and their translational barriers

Article Title: Dietary phytochemicals targeting neuroinflammation: mechanisms, bioavailability and translational challenges

Article References: Bhat, K. M. R., Upadhya, R., Nayak, A., Konuri, A., S. E., P. K., Adiga, M., Rao, V. K., & Upadhya, D. (2026). Dietary phytochemicals targeting neuroinflammation: mechanisms, bioavailability and translational challenges. Frontiers in Pharmacology, 17, Article 1943126. https://doi.org/10.3389/fphar.2026.1943126

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1943126

Keywords: neuroinflammation, oxidative stress, phytochemicals, bioavailability, preclinical studies, herbal medicines, reactive oxygen species, glial cells, clinical translation, drug safety, neurological disorders, drug development